Wockhardt Limited
WOCKPHARMA
Rangering i aksjer
#4519
Wockhardt Limited, together with its subsidiaries, operates as a pharmaceutical... Wockhardt Limited, together with its subsidiaries, operates as a pharmaceutical and biotech company, in India, the United States, the United Kingdom, Switzerland, Ireland, Russia, Europe, and internationally. It manufactures and trades pharmaceuticals, medicinal chemical, and botanical products, as well as chemicals and chemical products. The company also develops its flagship antibiotic, ZAYNICH zidebactam/cefepime, a novel beta lactam enhancer mechanism for the treatment of sepsis and hospital/ventilator associated pneumonia; FOVISCU, an antibiotic for gram-negative infections; MIQNAF nafithromycin, which targets azithromycin-resistant community respiratory pathogens; and ODRATE, a once-daily combination of ertapenem and zidebactam for resistant gram-negative infections through outpatient parenteral antimicrobial therapy. In addition, it develops and commercializes insulin analogs, glucagon-like peptide-1 agonists, and novel combination drug products; Biovac-B, a recombinant hepatitis-B vaccine; Wepox, a recombinant human erythropoietin; Wosulin, a recombinant human insulin; and Glaritus, a recombinant insulin glargine. Further, the company offers delivery devices for insulin, including Dispopen disposable pen and Mypen reusable pen. Wockhardt Limited was founded in 1967 and is headquartered in Mumbai, India.
Aksjekurs
$21.04
Sist synkronisert: 2026-10-19
Markedsverdi
$3.42B
Endring (1 dag)
-2.39%
Endring (1 år)
34.90%
Land
IN
Handel Wockhardt Limited (WOCKPHARMA)
Kategori
Healthcare
P/S-forhold for Wockhardt Limited (WOCKPHARMA)
P/S-forhold per October 2026 TTM: 8.92
Ifølge Wockhardt Limited sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/S-forhold (TTM) 8.92. Ved slutten av 2024 hadde selskapet et P/S-forhold på 3.05.
P/S-historikk for Wockhardt Limited fra 2004 til 2026
P/S-forhold ved hvert års slutt
| År | P/S-forhold | Endre |
|---|---|---|
| 2026 (TTM) | 8.92 | 20.16% |
| 2025 | 7.42 | 143.29% |
| 2024 | 3.05 | 264.90% |
| 2023 | 0.84 | -15.53% |
| 2022 | 0.99 | -46.30% |
| 2021 | 1.84 | 151.79% |
| 2020 | 0.73 | -44.52% |
| 2019 | 1.32 | -42.22% |
| 2018 | 2.28 | 6.29% |
| 2017 | 2.15 | -17.82% |
| 2016 | 2.62 | -47.40% |
| 2015 | 4.97 | 340.80% |
| 2014 | 1.13 | -73.70% |
| 2013 | 4.29 | 178.30% |
| 2012 | 1.54 | 50.46% |
| 2011 | 1.02 | 179.89% |
| 2010 | 0.37 | 1.87% |
| 2008 | 0.36 | -80.81% |
| 2007 | 1.87 | -22.86% |
| 2006 | 2.43 | -34.99% |
| 2005 | 3.73 | 10.06% |
| 2004 | 3.39 | 0.00% |
P/S-forhold for lignende selskaper eller konkurrenter
| Selskap | P/S-forhold | Forskjell i P/S-forhold | Land |
|---|---|---|---|
| 10.31 | 15.65% |
US
|
|
| - | - |
SE
|
|
| - | - |
FR
|
|
| - | - |
IT
|
|
| 15.12 | 69.62% |
US
|
